Sign inJoin waitlistJoin the waitlist

Aaron Lisberg

Thoracic Medical Oncologist · University of California, Los Angeles

Credentials: · · · ·

History

University of California, Los Angeles
Present

UCLA School of Medicine
Until 2017
University of Washington School of Medicine
Until 2014
University of Washington School of Medicine
Until 2012
University of Minnesota GME
2011

Research

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
The Lancet Oncology · 2017 · 903 citations
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Journal of Thoracic Oncology · 2018 · First of 26 authors · 511 citations
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Annals of Oncology · 2019 · 326 citations

Edward Garon
28 papers
Jonathan Goldman
12 papers
Amy Cummings
9 papers
Maria Velez
8 papers · 5 as a resident
Jacob Sands
6 papers
JC
James Carroll
6 papers
Steven Dubinett
6 papers
Rebecca Heist
5 papers
Arjan Gower
4 papers
Fereidoun Abtin
4 papers
Jaklin Gukasyan
4 papers
SG
Scott Genshaft
4 papers

Grants

Investigating Mitochondrial Networks as a Critical Determinant of Response to Antibody Drug Conjugates in Advanced NSCLC
National Cancer Institute · R01
Contact PI · $1.1M · University of California Los Angeles
2025–2030
Intratumoral Administration of CCL21-Gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
National Cancer Institute · K08
Contact PI · $1.3M · University of California Los Angeles
2020–2026

Clinical trials

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1
Whitehawk Therapeutics, Inc.
2025–2028